![]() | |
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C25H26N4O4 |
Molar mass | 446.507 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Otamixaban ( INN) is an experimental injectable anticoagulant direct factor Xa inhibitor [1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial. [2] [3]
Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.